Mylan announced the U.S FDA's final approval of its Abbreviated New Drug Application (ANDA) for repaglinide tablets (0.5, 1, and 2 mg), the generic version of Novo Nordisk's (Denmark) Prandin, indicated for glycemic control in adults with type 2 diabetes adjunct to diet and exercise. Furthermore, Mylan has now launched the generic product in the United States.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.84 USD | +4.04% |
|
+8.72% | +9.33% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.33% | 13.55B | |
+55.35% | 848B | |
+31.64% | 627B | |
-0.10% | 363B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+4.31% | 167B |
- Stock Market
- Equities
- VTRS Stock
- News Viatris Inc.
- Mylan Launches Generic Version of Novo Nordisk's Diabetes Drug Prandin